Why Natera (NTRA) Is Down 5.9% After Raising 2026 Guidance But Posting a Wider Q1 Loss

Natera, Inc. reported past first-quarter 2026 results with revenue rising to US$696.64 million from US$501.83 million a year earlier, while net loss widened to US$85.09 million and basic loss per share from continuing operations increased to US$0.60.
The company delivered record testing volumes, raised its 2026 revenue and gross margin guidance, yet reported a larger loss as operating expenses for clinical trials, new products and international expansion increased.
We’ll now examine how...